drugset / Trial / NCT06465238

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NCT06465238

Phase 2 Not yet recruiting 30 enrolled Henan Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label Phase II clinical trial to evaluate the safety and efficacy of SHR-A1921 or SHR-A2009 in patients with advanced NSCLC who progressed after standard therapy.

Timeline

Start
2024-06
Primary completion
2026-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-A1921 Monoclonal antibody Intravenous
Subject SHR-A2009 Other / unclassified Intravenous